ArticleBMJ mental health2026
Regulatory reform and adult methylphenidate dispensing in France: a nationwide interrupted time-series study.
Article in BMJ mental health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrance reports markedly lower adult attention-deficit/hyperactivity disorder (ADHD) medication use than other high-income countries despite similar prevalence. Methylphenidate is the predominant ADHD medication dispensed in France, accounting for the large majority of stimulant prescriptions in adults. Until recently, methylphenidate initiation was restricted to hospital specialists and largely excluded adult indications. Regulatory changes between 2021 and 2023 expanded adult access.
objectiveExamine national trends in adult methylphenidate dispensing in France and quantify the impact of the November 2021 regulatory reform.
methodsNationwide retrospective cohort study using the French National Health Data System (SNDS), including adults (≥18 years) with at least one community pharmacy dispensation of methylphenidate between January 2015 and December 2024. Weekly population-standardised dispensing rates were analysed using interrupted time-series models (quasi-Poisson) to estimate level and trend changes, stratified by sex and prescriber specialty. A secondary analysis examined incident treatment initiation to distinguish new users from individuals continuing pre-existing therapy.
findingsBetween 2015 and 2024, a total of 195 393 adults received methylphenidate. Before the reform, weekly dispensing grew gradually (~0.2% per week). At reform implementation, an immediate 10.9% level increase occurred, followed by a sustained acceleration (~0.7% per week), largely driven by new treatment initiations. Similar patterns were seen in both sexes, though the immediate increase was greater for dispensing attributed to psychiatrists.
conclusionsThe November 2021 reform was associated with a rapid and sustained expansion of adult methylphenidate use over the 3 years following the reform, primarily through increased treatment initiation, suggesting that prior regulatory constraints largely explained historically low treatment rates. Longer follow-up will be needed to assess whether this trajectory is maintained. CLINICAL IMPLICATIONS: Regulatory changes expanding ADHD treatment access may produce rapid prescribing increases, requiring adequate specialist capacity and stimulant use monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.